BDNF

BDNF Molekülinformation

Englischer Name	Brain-derived neurotrophic factor	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	8	Target-Alias	Brain-Derived Neurotrophic Factor，Abrineurin，ANON2，Brain Derived Neurotrophic Factor，BULN2，ProBDNF，Neurotrophin
Höchste Forschungs- und Entwicklungsphase	Phase 3 Clinical

Englischer Name	Brain-derived neurotrophic factor
Target-Alias	Brain-Derived Neurotrophic Factor，Abrineurin，ANON2，Brain Derived Neurotrophic Factor，BULN2，ProBDNF，Neurotrophin
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	8
Höchste Forschungs- und Entwicklungsphase	Phase 3 Clinical

BDNF Produktliste

Attribut
Protein (4)
Produktbibliothek
Online (4)
Spezies
Human (4)
Etikett
Tag Free (4)
Marker
Unconjugated (4)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
HOT GMP-BDFH15	Human	E. coli	GMP Human BDNF Protein (E. coli)	In den Warenkorb legen
BDF-H5116	Human	E. coli	Human BDNF / Abrineurin Protein (E. coli), premium grade	In den Warenkorb legen
BDF-H5117	Human	E. coli	Human BDNF / Abrineurin Protein (E. coli), Research Grade	In den Warenkorb legen
BDF-H5219	Human	HEK293	Human BDNF / Abrineurin Protein (HEK293), premium grade	In den Warenkorb legen

Gesamtmenge4

Produktanfrage

BDNF Molekülhintergrund

Brain-derived neurotrophic factor (BDNF) along with nerve growth factor (NGF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5) are members of the neurotrophin family of trophic factors. The neurotrophins play essential roles in the development, survival, and function of a wide range of neurons in both the peripheral and central nervous systems. The neurotrophins interact with two cell surface receptors, the low affinity P75 receptor and the Trk family of high affinity tyrosine kinase receptors. NGF preferentially binds TrkA, BDNF and NT4/5 bind TrkB, and NT-3 binds TrkC (and TrkA to a lesser extent).

BDNF Molekülalias

BDNF,ANON2,BULN2,Abrineurin

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Tetramethylpyrazine Nitrone		Phase 3 Clinical	Jinan University	Amyotrophic Lateral Sclerosis; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Ischemic Stroke	Details
JS1-1-01	JS1-1-01	Phase 3 Clinical	Tianjin Tasly Pharmaceutical Co Ltd	Depression; Depressive Disorder; Depressive Disorder, Major	Details
ACT-01	ACT-01; OCS-05; BN-201; G-79	Phase 2 Clinical	Promius Pharma	Keratosis, Actinic; Optic Neuritis	Details
Aldifen	MP101; NSC-1532; MP-101	Phase 2 Clinical	Mitochon Pharmaceuticals	Amyotrophic Lateral Sclerosis; Huntington Disease; Multiple Sclerosis	Details
ALTO-100	ALTO-100	Phase 2 Clinical	Alto Neuroscience Inc	Bipolar I Disorder; Bipolar II Disorder; Depressive Disorder, Major; Stress Disorders, Post-Traumatic	Details
AC-102	AC-102	Phase 2 Clinical	AudioCure Pharma GmbH	Hearing Loss, Sensorineural; Hearing Loss, Sudden; Tinnitus	Details
Laquinimod Sodium	TV-5600; ABR-215062; SAIK-MS	Phase 1 Clinical	Active Biotech Ab	Arthritis; Crohn Disease; Eye Diseases; Huntington Disease; Lupus Nephritis; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Uveitis	Details
AAV2-BDNF gene therapy (University Of California San Diego)		Phase 1 Clinical	University Of California San Diego	Alzheimer Disease; Cognitive Dysfunction	Details